



To,

Date: 27.05.2022

BSE Limited
P. J. Towers, Dalal Street
Mumbai - 400001
Dear Sir,

Sub: Outcome of Board Meeting held on 27.05.2022

Ref: Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited, this is to inform the exchange that at the Board Meeting of Hindustan Bio Sciences Limited held on Friday, 27.05.2022 at 02:00 P.M. at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034, Telangana, considered and approved the following items of business:

1. Audited Financial results for the year ended 31st March, 2022. (Attached)
2. Auditors Report along with declaration as per Regulation 33 of SEBI (LODR) regulations, 2015 for the year ended 31st March, 2022 (Attached)
3. Appointment of Mr. V B S S Prasad, as Secretarial Auditor of the company for the financial year 2022-23
4. Appointment of Mr. G B K Viswanadham as internal auditor of the company for the financial year 2022-23.
5. Accepted the resignation of Mrs. T. Kamala Kumar, the Company Secretary-cum-Compliance officer of the company and ratified the appointment of Mrs. Mansa Thakur as the Company Secretary-cum-Compliance officer of the company with effect from 01-05-2022.

The meeting concluded at 3:30 PM

This is for your information and records.

Thanking you.

For and on behalf of
Hindustan Bio Sciences Limited

Venkata Rama Mohan Raju Jangam
Managing Director
(DIN: 00060800)



HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564



Date: 27-05-2022

To
BSELimited,
PhirozeJeejeebhoy Towers,
Dalal Street, MUMBAI - 400 001.

Dear Sir / Madam,

Sub: Declaration pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulations,
2015


Ref: Hindustan Bio Sciences Limited (Scrip Code: 532041)

I J V R Mohan Raju Managing Director of Hindustan Bio Sciences Limited hereby
declare that the statutory auditors of the company, M/s. C Ramachandram & Co.,
Chartered Accountants have issued an audit report with unmodified/unqualified opinion
on audited financial results of the company for the year ended 31st March, 2022.

This declaration is issued in compliance of regulation 33 (3) (d) of the SEBI (LODR)
Regulations, 2015

Thanking you

For and on behalf of
Hindustan Bio Sciences Limited


Venkata Rama Mohan Raju Jampana
Managing Director
(DIN: 00060800)



HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564

HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171
STATEMENT OF AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2022

Sl. No.	Particulars	Quarter ended			Rs. In Lakhs	
		31.03.2022 (Audited)	31-12-2021 (unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
1	Income from Operations					
	(a) Revenue from operations	0.27	23.96	14.98	43.65	103.19
	(b) Other Income	-	-	-	5.24	-
	Total Revenue (1)	0.27	23.96	14.98	48.89	103.19
2	Expenses					
	(a) cost of material consumed	-	-	-	-	-
	(b) Purchases of Stock -in-trade	-	15.90	-	28.93	34.03
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	-	-	10.06	-	34.01
	(d) Employee Benefit Expenses	5.94	5.93	6.32	24.05	24.64
	(e) Finance Costs	0.22	0.13	0.01	0.50	0.69
	(f) Selling Expenses	-	0.38	-	0.51	0.52
	(g) Depreciation and amortisation Expenses	0.10	0.08	0.31	0.34	0.80
	(h) Amount written off	-	-	80.23	-	80.23
	(i) Other Expenses	32.19	1.74	10.21	45.91	23.70
	Total Expenses (2)	38.45	24.16	107.16	100.34	198.72
3	Profit/(Loss) before Exceptional & Extraordinary items and tax (1-2)	(38.18)	(0.20)	(92.18)	(51.45)	(95.53)
4	Exceptional Items	-	-	-	-	-
5	Profit/(Loss) before tax (3-4)	(38.18)	(0.20)	(92.18)	(51.45)	(95.53)
6	Tax Expenses					
	(a) Current Tax	-	-	-	-	-
	(b) Previous Taxes	-	-	1.68	0.03	1.68
	(c) Deferred Tax	0.34	-	0.13	0.34	0.13
7	Profit/(Loss) for the period from continuing operations (5-6)	(38.52)	(0.20)	(90.63)	(51.76)	(93.98)
8	Profit/(Loss) from discontinued operations	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-
10	Profit/(Loss) from Discontinued operations after tax (8-9)	-	-	-	-	-
11	Profit/(Loss) for the period (7+10)	(38.52)	(0.20)	(90.63)	(51.76)	(93.98)
12	Other Comprehensive Income					
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(2) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit/(Loss) and other comprehensive income for the period)	(38.52)	(0.20)	(90.63)	(51.76)	(93.98)
14	Paid up Equity Capital (Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	(894.62)
16	Earnings per equity share for continuing operations					
	(A) Basic	(0.38)	(0.00)	(0.88)	(0.50)	(0.92)
	(B) Diluted	(0.38)	(0.00)	(0.88)	(0.50)	(0.92)
17	Earnings per equity share for discontinuing operations					
	(A) Basic	-	-	-	-	-
	(B) Diluted	-	-	-	-	-
18	Earnings per equity share (for discontinuing & continuing operations)					
	(A) Basic	(0.38)	(0.00)	(0.88)	(0.50)	(0.92)
	(B) Diluted	(0.38)	(0.00)	(0.88)	(0.50)	(0.92)



HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171
STATEMENT OF ASSETS AND LIABILITIES

PARTICULARS	Rs. in Lakhs	
	As at	
	31.03.2022	31.03.2021
1. ASSETS		
Non Current Assets		
(a) Property, Plant and Equipment	3.98	3.97
(b) Deferred Tax Asset	0.56	0.90
(c) Other Financial Assets	238.97	238.97
Total Non Current Assets	239.53	239.87
Current Assets		
(a) Inventory	0	0
(b) Financial Assets		
(i) Trade Receivables	13.50	61.73
(ii) Cash and Cash Equivalents	0.91	1.67
(c) Other Current Assets	39.66	41.39
Sub Total Current Assets	54.07	104.79
TOTAL ASSETS	297.58	348.63
2. EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	1025.08	1025.08
(b) Other Equity	(946.37)	(894.62)
Total Equity	78.71	130.46
Non Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	107.17	73.30
Total Non Current Liabilities	107.17	73.30
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	109.48	112.58
(ii) Trade Payables		
A) Total Outstanding dues of MSME	0	0
B) Total Outstanding dues of Creditors other than MSME	0.12	29.12
b) Provisions	2.10	3.17
Total Current Liabilities	111.70	144.87
TOTAL EQUITY AND LAIBILITIES	297.58	348.63

Note:

1. The Audited Financial Results were taken on record by the Board of Directors in their meeting held on 27.05.2022
2. Previous Year figures have been regrouped wherever necessary.

Hyderabad
27.05.2022

for Hindustan Bio Sciences Limited

J.V.R.Mohan Raju
Managing Director



HINDUSTAN BIO SCIENCES LIMITED

Cash Flow Statement for the year ended 31st March,2022 (Rs. In lakhs)		
Particulars	31st March 2022	31st March 2021
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) Before Tax	(51.45)	(95.53)
Adjustments for:		
Provision for Debtors	22.70	
Depreciation	0.34	0.80
Operating Profit before Working Capital Changes	(28.41)	(94.73)
Movements in Working Capital		
Increase/(Decrease) in Trade Payables	(28.99)	(37.00)
Decrease/(Increase) in Provisions	(1.07)	(2.35)
Increase/(Decrease) in Borrowings	(3.10)	19.49
Increase/(Decrease) in Trade Receivables	25.53	74.59
Increase/(Decrease) in Inventories	-	34.00
Decrease/(Increase) in Other financial assets	-	80.23
Decrease/(Increase) in Other current assets	1.73	(0.61)
Cash generated from operations	(34.31)	73.62
Less: Income Tax Refund/paid	0.03	(1.68)
Net Cash flow from Operating activities	(34.28)	75.30
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(0.35)	-
Net Cash used in Investing activities	(0.35)	-
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long term Borrowings	33.87	(93.30)
Interest paid		-
Net Cash used in financing activities	33.87	(93.30)
Net increase in cash & Cash Equivalents	(0.76)	(18.00)
Cash and Cash equivalents at the beginning of the year	1.67	19.67
Cash and Cash equivalents at the end of the year	0.91	1.67

The above Cash Flow statement has been prepared using the Indirect Method as set out in Accounting Standard 3 on Cash Flow Statement.
for Hindustan Bio Sciences Limited

J.V.R.Mohan Raju
Managing Director

PLACE: Hyderabad
DATE : 27-05-2022



C. RAMACHANDRAM & CO.
CHARTERED ACCOUNTANTS

Plot No. 539, South Samudra,
2nd Floor, Kakatiya Hills,
Madhapur, Hyderabad - 500 081.
Phone : 040-42212099
E-mail : crco@crco.in
Web : www.crco.in

Independent Auditor's Report On Audit Of Standalone Financial Results

To the Board of Directors of Hindustan Bio Sciences Limited

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **Hindustan Bio Sciences Limited** (the "Company"), for the three months and year ended March 31, 2022 (the Statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2022.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA's") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Branch Office : No. 87, 2nd Floor, 21st Cross, 7th Main, N.S. Palya,

Hyderabad - 500 076. Ph : 040-40971918 E-mail : crcoahd@gmail.com

Management's Responsibilities for the Standalone Financial Results

This Statement is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim condensed standalone financial statements for the year ended March 31, 2022. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our



work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

For **C. RAMACHANDRAM & CO.**

Chartered Accountants

Firm Registration No. 002864S

N. Madhusudan Reddy

N MADHUSUDAN REDDY

Partner

Membership No. 241624

UDIN: 22241624AJTAQL6159



Place: Hyderabad

Date: May 27, 2022